Literature DB >> 2838337

Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma.

D A McPhee1, B E Kemp, S Cumming, D Stapleton, I D Gust, R R Doherty.   

Abstract

A series of synthetic peptides corresponding to segments of HIV encoded proteins were selected using criteria described by Welling et al. [(1985) FEBS Lett. 188, 215]. Synthetic peptide analogs to gp120 (2-13), (55-65), gp41 (582-596) (659-670) and tatIII (71-83) were recognized by 41-67% of sera or plasma from individuals known to be infected with HIV on the basis of virus isolation or Western blot screening. The peptide which reacted with most sera or plasma was gp41 (582-596), a conserved region in the transmembrane glycoprotein. An extended peptide analog, gp41 (579-599), tested against the same samples showed almost 100% reactivity, confirming independent studies identifying a highly immunodominant region of gp41. There was an unexpected high prevalence of antibodies (25%) to the tatIII peptide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838337     DOI: 10.1016/0014-5793(88)80468-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Structural gene and complete amino acid sequence of Vibrio alginolyticus collagenase.

Authors:  H Takeuchi; Y Shibano; K Morihara; J Fukushima; S Inami; B Keil; A M Gilles; S Kawamoto; K Okuda
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

2.  Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera.

Authors:  U Wieland; J E Kühn; C Jassoy; H Rübsamen-Waigmann; V Wolber; R W Braun
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

3.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.

Authors:  B J Pollock; A S McKenzie; B E Kemp; D A McPhee; A J D'Apice
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.